XM n’offre pas ses services aux résidents des États-Unis d’Amérique.

US nuclear plant unfit for quick resurrection, former lead engineer says



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>US nuclear plant unfit for quick resurrection, former lead engineer says</title></head><body>

By Timothy Gardner

WASHINGTON, Aug 2 (Reuters) -The first U.S. nuclear plant to ever try reopening after undergoing preparations for permanent closure is not fit to restart anytime soon because it sidestepped important safety work for years before retirement, a former official at the reactor said.

Power company Entergy ETR.N closed the Palisades reactor in Michigan in 2022, after the plant generated electricity for more than 50 years. Privately-held Holtec International bought Palisades shortly after and has since secured a $1.52 billion conditional U.S. loan guarantee to restart. Holtec seeks to open the plant in about a year.

The fate of Palisades is closely watched by the nuclear industry as at least two other shuttered plants, including a unit at Constellation Energy's CEG.O Three Mile Island, consider reopening.

The administration of President Joe Biden sees nuclear power as a critical tool in the fight against climate change and supports efforts to restart closed plants, delay retirements of existing ones, and speed permitting for new projects.

"I'm pro-nuclear, but they selected the wrong horse to ride to town on," said Alan Blind, who was engineering director at the Palisades plant from 2006 to 2013 under Entergy.

Blind said the plant got exemptions from the U.S. Nuclear Regulatory Commission, the nuclear safety regulator, allowing it to fall short of safety design standards that more modern plants must adhere to because it was nearing retirement.

Those safety standards include prevention of cooling systems being clogged by the breakdown of insulation on pipes, defense against earthquakes, and reduction of risks to fires, Blind said, adding he had been monitoring the plants’ exemption requests since his retirement.

"I'm worried that the NRC will not insist that the generic safety issues be the fixed before they allow Palisades to restart," Blind told Reuters.

Scott Burnell, an NRC spokesperson, said the safety review of Holtec's applications "will include examining how Holtec plans to follow through on technical issues, such as what Mr. Blind describes, that were unresolved when the plant shut down in 2022."

"Those plans will be public to the greatest extent possible," and the NRC will allow a restart only if Holtec meets safety and environmental requirements. Burnell added NRC will soon offer an opportunity to offer legal challenges to Holtec's requests to restart, a standard procedure.

Holtec believes Palisades can restart in about a year within the NRC's existing regulatory framework, said spokesperson Pat O'Brien. "As part of the repowering, Palisades will undergo extensive inspections, testing, maintenance, system and equipment upgrades and modifications to ensure the continuation of safe and reliable operation throughout the plant’s extended operational life," O'Brien said.

Entergy supports the effort to re-open Palisades, said spokesperson Mark Sullivan. He did comment on Blind's concerns about safety standards at the plant.

Entergy shut Palisades in May 2022, two weeks ahead of schedule over a glitch with a control rod, despite a $6 billion federal program to save nuclear plants suffering from rising costs and competition from natural gas and renewable energy.

The Biden administration's Loan Programs Office at the Department of Energy issued Holtec a conditional $1.52 billion loan guarantee in March to restart Palisades.

The LPO referred questions to the NRC.



Reporting by Timothy Gardner, Editing by Nick Zieminski

</body></html>

Avertissement : Les entités de XM Group proposent à notre plateforme de trading en ligne un service d'exécution uniquement, autorisant une personne à consulter et/ou à utiliser le contenu disponible sur ou via le site internet, qui n'a pas pour but de modifier ou d'élargir cette situation. De tels accès et utilisation sont toujours soumis aux : (i) Conditions générales ; (ii) Avertissements sur les risques et (iii) Avertissement complet. Un tel contenu n'est par conséquent fourni que pour information générale. En particulier, sachez que les contenus de notre plateforme de trading en ligne ne sont ni une sollicitation ni une offre de participation à toute transaction sur les marchés financiers. Le trading sur les marchés financiers implique un niveau significatif de risques pour votre capital.

Tout le matériel publié dans notre Centre de trading en ligne est destiné à des fins de formation / d'information uniquement et ne contient pas – et ne doit pas être considéré comme contenant – des conseils et recommandations en matière de finance, de fiscalité des investissements ou de trading, ou un enregistrement de nos prix de trading ou une offre, une sollicitation, une transaction à propos de tout instrument financier ou bien des promotions financières non sollicitées à votre égard.

Tout contenu tiers, de même que le contenu préparé par XM, tels que les opinions, actualités, études, analyses, prix, autres informations ou liens vers des sites tiers contenus sur ce site internet sont fournis "tels quels", comme commentaires généraux sur le marché et ne constituent pas des conseils en investissement. Dans la mesure où tout contenu est considéré comme de la recherche en investissement, vous devez noter et accepter que le contenu n'a pas été conçu ni préparé conformément aux exigences légales visant à promouvoir l'indépendance de la recherche en investissement et, en tant que tel, il serait considéré comme une communication marketing selon les lois et réglementations applicables. Veuillez vous assurer que vous avez lu et compris notre Avis sur la recherche en investissement non indépendante et notre avertissement sur les risques concernant les informations susdites, qui peuvent consultés ici.

Avertissement sur les risques : votre capital est à risque. Les produits à effet de levier ne sont pas recommandés pour tous. Veuillez consulter notre Divulgation des risques